The reported statements, read against the company's own industry.
Financials view
Market Capitalization
732.77MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Revenue (TTM)
339.92MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Profit Margin
-3.77%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Beta
0.9960x
vs all stocks
Updated Jul 18, 2026
52-Week Change
44.50%
vs all stocks
Updated Jul 18, 2026
Market Capitalization
732.77MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Enterprise Value
507.81MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Forward P/E
-25.25x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Price to Sales (TTM)
2.16x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Price to Book (MRQ)
1.59x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Enterprise to Revenue
1.49x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Enterprise to EBITDA
-27.67x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 51.41×.Updated Jul 18, 2026
Gross Margin
75.46%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 77.88%.Updated Jul 18, 2026
Profit Margin
-3.77%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Operating Margin
-22.00%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Return on Assets (TTM)
-3.96%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Return on Equity (TTM)
-2.85%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Revenue (TTM)
339.92MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Revenue per Share (TTM)
11.60USDUpdated Jul 18, 2026
Quarterly Revenue Growth
-4.90%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Gross Profit (TTM)
264.74MUSD
vs all stocks (USD)
Updated Jul 18, 2026
EBITDA (TTM)
9.88MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Net Income (TTM)
-12.83MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Quarterly Earnings Growth (YoY)
-4.90%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Operating Cash Flow (TTM)
48.25MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Levered Free Cash Flow (TTM)
12.89MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Jul 18, 2026
Payout Ratio
0.00%
vs Diagnostics & Research peers
Updated Jul 18, 2026
Revenue
344.23MUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
71.03MUSDFY2025 · Dec 31, 2025
Gross Profit
273.20MUSDFY2025 · Dec 31, 2025
Operating Income
-42.81MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-29.51MUSDFY2025 · Dec 31, 2025
Income Tax Expense
-5.36MUSDFY2025 · Dec 31, 2025
Net Income
-24.16MUSDFY2025 · Dec 31, 2025
EBIT
-29.43MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
9.88MUSDFY2025 · Dec 31, 2025
Research & Development
51.85MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
229.32MUSDFY2025 · Dec 31, 2025
Non-operating Interest Income
11.77MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
86.00KUSDFY2025 · Dec 31, 2025
EPS (Basic)
-0.8300USDFY2025 · Dec 31, 2025
EPS (Diluted)
-0.8300USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
28.99MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
28.99MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-24.16MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
63.97MUSDFY2025 · Dec 31, 2025
Free Cash Flow
28.00MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
116.73MUSDFY2025 · Dec 31, 2025
Income Tax Paid
1.60MUSDFY2025 · Dec 31, 2025
Interest Paid
59.00KUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-24.16MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
40.77MUSDFY2025 · Dec 31, 2025
Deferred Taxes (CF)
-6.23MUSDFY2025 · Dec 31, 2025
Stock-based Compensation
45.89MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
153.00KUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
6.88MUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
3.08MUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-2.41MUSDFY2025 · Dec 31, 2025
Capital Expenditures
-35.98MUSDFY2025 · Dec 31, 2025
Net Acquisitions
-18.73MUSDFY2025 · Dec 31, 2025
Purchase of Investments
-188.71MUSDFY2025 · Dec 31, 2025
Sale of Investments
190.73MUSDFY2025 · Dec 31, 2025
Other Investing Activity
-7.68MUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
-60.37MUSDFY2025 · Dec 31, 2025
Long-term Debt Issuance
190.00KUSDFY2025 · Dec 31, 2025
Long-term Debt Payments
-115.00KUSDFY2025 · Dec 31, 2025
Other Financing Charges
-11.66MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
-11.58MUSDFY2025 · Dec 31, 2025
Shares Outstanding
30.30MSharesUpdated Jul 18, 2026
Float Shares
26.79MSharesUpdated Jul 18, 2026
Shares Short
1.49MSharesUpdated Jul 18, 2026
Short Ratio
3.95days
vs all stocks
Updated Jul 18, 2026
Short % of Shares Outstanding
5.04%
vs all stocks
Updated Jul 18, 2026
% Held by Insiders
2.73%
vs all stocks
Updated Jul 18, 2026
% Held by Institutions
92.43%
vs all stocks
Updated Jul 18, 2026
Total Cash (MRQ)
261.68MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Total Cash per Share (MRQ)
8.63USDUpdated Jul 18, 2026
Total Debt (MRQ)
36.72MUSD
vs all stocks (USD)
Updated Jul 18, 2026
Total Debt to Equity (MRQ)
0.0796x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Current Ratio (MRQ)
6.75x
vs Diagnostics & Research peers
Updated Jul 18, 2026
Book Value per Share (MRQ)
15.23USDUpdated Jul 18, 2026
Total Assets
578.56MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
361.10MUSDFY2025 · Dec 31, 2025
Total Liabilities
107.68MUSDFY2025 · Dec 31, 2025
Total Non-current Assets
217.46MUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
39.01MUSDFY2025 · Dec 31, 2025
Total Current Liabilities
68.68MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
116.73MUSDFY2025 · Dec 31, 2025
Other Short-term Investments
182.78MUSDFY2025 · Dec 31, 2025
Accounts Receivable
43.38MUSDFY2025 · Dec 31, 2025
Inventory
10.25MUSDFY2025 · Dec 31, 2025
Accounts Payable
18.71MUSDFY2025 · Dec 31, 2025
Short-term Debt
1.74MUSDFY2025 · Dec 31, 2025
Other Current Liabilities
3.13MUSDFY2025 · Dec 31, 2025
Long-term Debt
35.17MUSDFY2025 · Dec 31, 2025
Other Non-current Liabilities
1.50MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
30.00KUSDFY2025 · Dec 31, 2025
Retained Earnings
-224.28MUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
470.87MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
14.59USDUpdated Jul 18, 2026
52-Week High
44.28USDUpdated Jul 18, 2026
52-Week Change
44.50%
vs all stocks
Updated Jul 18, 2026
Beta
0.9960x
vs all stocks
Updated Jul 18, 2026
50-Day MA
21.57USDUpdated Jul 18, 2026
200-Day MA
28.76USDUpdated Jul 18, 2026
Avg 10-Day Volume
265.04KSharesUpdated Jul 18, 2026
Avg 30-Day Volume
325.91KSharesUpdated Jul 18, 2026
Diluted EPS (TTM)
-0.4200USDUpdated Jul 18, 2026
Other Income / Expense
1.61MUSDFY2025 · Dec 31, 2025
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 6.75×, higher than 95% of its Diagnostics & Research peers (median 2.44×)Significant
Current ratio: 6.75Industry median: 2.44Industry P95: 6.08Peers compared: 31.00
Structural Tensions
High gross margins eroded by operating costsNotable